Gene therapy has been out of favor but we're finally getting to the point where the products are in later stage clinical trials. |
I think it's probably almost 50-50 the FDA says, 'go ahead and give us the documentation for filing,' ... The problem is that historically the FDA's always gotten more difficult in these cases. |
It's very likely to be approved. |
My sense is that the FDA's response to all this publicity is to slow down and be even more careful, ... And that's absolutely the wrong thing to do. |
My sense is that the FDA's response to all this publicity is to slow down and be even more careful. And that's absolutely the wrong thing to do. |
the data is really good. |
The IPO window for biotech stocks is closing, |
The IPO window for biotech stocks is closing. |
The one rule I think is really important when you hear about a scientific discovery is don't buy any stock then -- but you may want to start investigating the company, |
There are stocks that are so cheap and many of them are trading below their cash value. |
There will be a lot of competition out there by the time these products get to market -- if they do. |
There's always risks when you haven't seen the clinical data. |
They would love to have the colorectal go ahead because that's a larger market, |
What happened is we went through a long period that was very difficult for biotech companies to raise money. Once this window opened, a lot of people decided that they would go ahead. |